Last reviewed · How we verify

ABT-493 coformulated with ABT-530

AbbVie · Phase 3 active Small molecule

ABT-493 coformulated with ABT-530 is a Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor Small molecule drug developed by AbbVie. It is currently in Phase 3 development for Chronic hepatitis C virus (HCV) infection, genotype 1-6. Also known as: ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET.

ABT-493 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication, coformulated with ABT-530 (an NS5A inhibitor) to enhance antiviral activity.

ABT-493 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication, coformulated with ABT-530 (an NS5A inhibitor) to enhance antiviral activity. Used for Chronic hepatitis C virus (HCV) infection, genotype 1-6.

At a glance

Generic nameABT-493 coformulated with ABT-530
Also known asABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET
SponsorAbbVie
Drug classDirect-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor
TargetHCV NS3/4A protease and NS5A protein
ModalitySmall molecule
Therapeutic areaVirology / Hepatology
PhasePhase 3

Mechanism of action

ABT-493 inhibits the HCV NS3/4A serine protease, which is essential for viral polyprotein processing and replication. The coformulation with ABT-530, an NS5A inhibitor, provides a direct-acting antiviral (DAA) combination that targets two distinct viral proteins, improving efficacy and reducing the risk of resistance development in hepatitis C treatment.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ABT-493 coformulated with ABT-530

What is ABT-493 coformulated with ABT-530?

ABT-493 coformulated with ABT-530 is a Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor drug developed by AbbVie, indicated for Chronic hepatitis C virus (HCV) infection, genotype 1-6.

How does ABT-493 coformulated with ABT-530 work?

ABT-493 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication, coformulated with ABT-530 (an NS5A inhibitor) to enhance antiviral activity.

What is ABT-493 coformulated with ABT-530 used for?

ABT-493 coformulated with ABT-530 is indicated for Chronic hepatitis C virus (HCV) infection, genotype 1-6.

Who makes ABT-493 coformulated with ABT-530?

ABT-493 coformulated with ABT-530 is developed by AbbVie (see full AbbVie pipeline at /company/abbvie).

Is ABT-493 coformulated with ABT-530 also known as anything else?

ABT-493 coformulated with ABT-530 is also known as ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET.

What drug class is ABT-493 coformulated with ABT-530 in?

ABT-493 coformulated with ABT-530 belongs to the Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor class. See all Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor drugs at /class/direct-acting-antiviral-daa-combination-ns3-4a-protease-inhibitor-ns5a-inhibitor.

What development phase is ABT-493 coformulated with ABT-530 in?

ABT-493 coformulated with ABT-530 is in Phase 3.

What are the side effects of ABT-493 coformulated with ABT-530?

Common side effects of ABT-493 coformulated with ABT-530 include Headache, Fatigue, Nausea, Diarrhea.

What does ABT-493 coformulated with ABT-530 target?

ABT-493 coformulated with ABT-530 targets HCV NS3/4A protease and NS5A protein and is a Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor.

Related